Sanofi 2013 SR
The 2013 CSR Report for Sanofi focuses on four strategic pillars: Patient, Ethics, People, and Planet. Key highlights include the launch of the StarBem platform in Brazil for diabetes patients and the large-scale production of semisynthetic artemisinin for malaria treatment. The company achieved an 11% reduction in combined Scope 1 and 2 emissions since 2010 and successfully integrated all pharmacovigilance systems into the AWARE global database. Sanofi also emphasized its commitment to human rights by publishing an internal guide for its 110,000 employees and renewed its materiality assessment to define its 2014-2017 roadmap.
Company: Sanofi
Sector: Health Care
Country: France
Year: 2013
Type: SR
Pages: 116
Back to company
Sanofi
Corporate Social Responsibility Report
The 2013 CSR Report for Sanofi focuses on four strategic pillars: Patient, Ethics, People, and Planet. Key highlights include the launch of the StarBem platform in Brazil for diabetes patients and the large-scale production of semisynthetic artemisinin for malaria treatment. The company achieved an 11% reduction in combined Scope 1 and 2 emissions since 2010 and successfully integrated all pharmacovigilance systems into the AWARE global database. Sanofi also emphasized its commitment to human rights by publishing an internal guide for its 110,000 employees and renewed its materiality assessment to define its 2014-2017 roadmap.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2013
Reporting Period
Jan 1, 2013 - Dec 31, 2013
Fiscal Year
2013
Published
Mar 6, 2014
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees